<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448903</url>
  </required_header>
  <id_info>
    <org_study_id>ROV-BEM-2006-01</org_study_id>
    <secondary_id>2006-005201-60</secondary_id>
    <nct_id>NCT00448903</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers</brief_title>
  <official_title>Multicentric, Randomized, Double-blind, Controlled Clinical Trial to Assess the Efficacy and Safety of Bemiparin Sodium as Treatment of Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rovi Pharmaceuticals Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rovi Pharmaceuticals Laboratories</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic foot ulcers are a common, severe and expensive complication in patients with diabetes
      and often causes lower-extremity amputation. The aim of this study is to evaluate the effect
      of bemiparin as treatment of diabetic foot ulcers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total healing with intact skin or a significant improvement defined as a reduction of ulcer area &gt; or = 50% or one degree reduction on Wagner Classification.</measure>
    <time_frame>90 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of major bleeding and the incidence of adverse events.</measure>
    <time_frame>210 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bemiparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemiparin</intervention_name>
    <description>Bemiparin sodium</description>
    <arm_group_label>A</arm_group_label>
    <other_name>RO-11</other_name>
    <other_name>Hibor</other_name>
    <other_name>Zibor</other_name>
    <other_name>Ivor</other_name>
    <other_name>Badyket</other_name>
    <other_name>Ivorat</other_name>
    <other_name>Ivormax</other_name>
    <other_name>Entervit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium Chloride 0,9%</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sodium Chloride</other_name>
    <other_name>physiological saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old who have given their informed consent to participate in the
             study.

          -  Patients with type I or II Diabetes Mellitus (ADA Criteria).

          -  Presence of chronic neuropathic inframalleolar diabetic foot ulcer (starting at least
             2 months before), grade I or II on Wagner Classification, without significant
             improvement (reduction of ulcer area &gt; or = 25%) within the past 15 days prior to
             inclusion.

          -  Ulcer size equal or bigger than 0.64 cm2 using the following formula: [Major axis] x
             [Minor axis]

          -  Ankle-brachial index (ABI) &gt; or = 0,7

        Exclusion Criteria:

          -  Patients with clinical symptoms of limb-threatening or life-threatening infection

          -  Presence of bone exposure at the bottom of the ulcer and/or bone palpation by catheter
             and/or presence of radiological signs of pathological fractures and/or bone sequesters

          -  Ankle-brachial index (ABI) &lt;0,7

          -  Subjects with arterial calcification (ABI &gt; 1,3) with negative tibial and foot pulse
             that for any cause the Toe/Arm index (T/A) cannot be measured by plethysmography
             (photoplethysmography or strain-gauge)

          -  Subjects with arterial calcification (ABI &gt; 1,3) with negative tibial and foot pulse
             and with T/A index &lt; 0,55 measured by plethysmography (photoplethysmography or
             strain-gauge)

          -  Patients with hematological disorders, organic lesions susceptible to bleeding (e.g.
             active peptic ulcer, stroke, aneurysms), severe arterial hypertension (systolic blood
             pressure over 200 mmHg and/or diastolic blood pressure over 120 mmHg).

          -  Patients with severe renal failure (creatinine clearance &lt;30 ml/min) or hepatic
             insufficiency (AST and/or ALT values &gt;5 times the normal value established by the
             reference ranges of the local hospital laboratory).

          -  Patients with connective tissue disease

          -  Acute bacterial endocarditis or slow endocarditis.

          -  Patients with antithrombin deficit and C and S protein deficit.

          -  Patients with HbA1C &gt; 12%.

          -  Women who are pregnant or breast-feeding, or with the possibility of becoming pregnant
             during the study.

          -  Known hypersensitivity to LMWH, heparin or substances of porcine origin.

          -  Patients with a history of heparin-induced thrombocytopenia.

          -  Patients on treatment with anticoagulant therapy at inclusion time or in the past 15
             days.

          -  Patients on treatment with pentoxifiline at inclusion time or in the past 30 days.

          -  Patients on treatment with systemic corticosteroid or immunosuppressive therapy at
             inclusion time or in the past 3 months.

          -  Patients on treatment with beclapermin at inclusion time or in the past 15 days.

          -  Patients that have suffered a revascularization or endovascular surgery two months
             prior to inclusion

          -  Patients with a life expectancy less than 6 months.

          -  Patients that cannot complete the scheduled follow-up visits or are not able to
             complete the study period.

          -  Patients who are participating in another clinical trial or have done it in the past
             30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JR March, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Getafe Hospital, E-28905 Getafe (Madrid) Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Marinel-lo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mataró Hospital, E-08304 Mataro (Barcelona) Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R Gómez Medialdea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Virgen de la Victoria Hospital, E-29010 Malaga, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CROATIA</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>POLAND</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ROMANIA</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RUSSIA</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SERBIA</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPAIN</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2007</study_first_submitted>
  <study_first_submitted_qc>March 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2007</study_first_posted>
  <last_update_submitted>March 16, 2011</last_update_submitted>
  <last_update_submitted_qc>March 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rovi Pharmaceuticals Laboratories</name_title>
    <organization>Medical Department</organization>
  </responsible_party>
  <keyword>diabetic</keyword>
  <keyword>foot</keyword>
  <keyword>ulcer</keyword>
  <keyword>bemiparin</keyword>
  <keyword>neuropathy</keyword>
  <keyword>neuroishemic</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

